Institution
Hospital Universitario La Paz
Healthcare•Madrid, Spain•
About: Hospital Universitario La Paz is a healthcare organization based out in Madrid, Spain. It is known for research contribution in the topics: Population & Medicine. The organization has 8960 authors who have published 11499 publications receiving 191509 citations.
Topics: Population, Medicine, Cancer, Transplantation, Haemophilia
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The findings support the conclusion that CX3CL1 acts as a positive modifier of breast cancer in concert with ErbB receptors, and this effect was important insofar as mammary tumorigenesis was delayed and tumor multiplicity was reduced by genetic deletion in HER2/neu mice, but not in polyoma middle T-antigen oncomice.
Abstract: Chemokines are relevant molecules in shaping the tumor microenvironment, although their contributions to tumorigenesis are not fully understood. We studied the influence of the chemokine CX3CL1/fractalkine in de novo breast cancer formation using HER2/neu transgenic mice. CX3CL1 expression was downmodulated in HER2/neu tumors, yet, paradoxically, adenovirus-mediated CX3CL1 expression in the tumor milieu enhanced mammary tumor numbers in a dose-dependent manner. Increased tumor multiplicity was not a consequence of CX3CL1-induced metastatic dissemination of the primary tumor, although CX3CL1 induced epithelial-to-mesenchymal transition in breast cancer cells in vitro. Instead, CX3CL1 triggered cell proliferation by induction of ErbB receptors through the proteolytic shedding of an ErbB ligand. This effect was important insofar as mammary tumorigenesis was delayed and tumor multiplicity was reduced by genetic deletion of CX3CL1 in HER2/neu mice, but not in polyoma middle T-antigen oncomice. Our findings support the conclusion that CX3CL1 acts as a positive modifier of breast cancer in concert with ErbB receptors.
67 citations
••
TL;DR: To evaluate the effectiveness of tapentadol prolonged release (PR) vs. oxycodone/naloxone PR in non–opioid‐pretreated patients with severe chronic low back pain with a neuropathic pain component, a comparison study is conducted.
Abstract: Objective
To evaluate the effectiveness of tapentadol prolonged release (PR) vs. oxycodone/naloxone PR in non–opioid-pretreated patients with severe chronic low back pain with a neuropathic pain component.
Methods
Eligible patients (average pain intensity [numerical rating scale-3 (NRS-3)] ≥6; painDETECT positive/unclear) were randomized to twice-daily tapentadol PR 50 mg or oxycodone/naloxone PR 10 mg/5 mg. After a 21-day titration (maximum twice-daily doses: tapentadol PR 250 mg, or oxycodone/naloxone PR 40 mg/20 mg plus oxycodone PR 10 mg), target doses were continued for 9 weeks. The primary effectiveness endpoint was the change in NRS-3 from baseline to final evaluation; the exact repeated confidence interval (RCI) for tapentadol PR minus oxycodone/naloxone PR was used to establish noninferiority (upper limit <1.3) and superiority (confirmatory analyses).
Results
For the primary effectiveness endpoint, tapentadol PR was noninferior to oxycodone/naloxone PR (97.5% RCI: [−1.820, −0.184]; P < 0.001). This exact RCI also yielded evidence of superiority for tapentadol PR vs. oxycodone/naloxone PR (significantly greater reduction in pain intensity; P = 0.003). Improvements (baseline to final evaluation) in painDETECT and Neuropathic Pain Symptom Inventory scores were significantly greater with tapentadol PR vs. oxycodone/naloxone PR (all P ≤ 0.005).
Conclusions
The study was formally shown to be positive and demonstrated, in the primary effectiveness endpoint, the noninferiority for tapentadol PR vs. oxycodone/naloxone PR. The effectiveness of tapentadol PR was superior to that of oxycodone/naloxone PR by means of clinical relevance and statistical significance (confirmatory evidence of superiority). Tapentadol PR was associated with significantly greater improvements in neuropathic pain-related symptoms and global health status than oxycodone/naloxone PR and with a significantly better gastrointestinal tolerability profile. Tapentadol PR may be considered a first-line option for managing severe chronic low back pain with a neuropathic pain component.
67 citations
••
TL;DR: PD solutions impaired monocyte‐MDDC differentiation, inhibiting the acquisition of DC markers such as CD1a and DC‐specific intercellular adhesion molecule‐3 grabbing nonintegrin (CD209), which have important implications for the initiation of immune responses under high lactate conditions.
Abstract: Peritoneal dialysis (PD) is a well-established therapy for end-stage renal failure, but its efficiency is limited by recurrent peritonitis. As PD solutions impair local inflammatory responses within the peritoneal cavity, we have analyzed their influence on the in vitro maturation of human monocyte-derived dendritic cells (MDDC). Evaluation of MDDC maturation parameters [expression of adhesion and costimulatory molecules, receptor-mediated endocytosis, allogeneic T cell activation, production of tumor necrosis factor alpha, interleukin (IL)-6 and IL-12 p70, and nuclear factor (NF)-kappaB activation] revealed that currently used PD solutions differentially inhibit the lipopolysaccharide (LPS)-induced maturation of MDDC, an inhibition that correlated with their ability to impair the LPS-stimulated NF-kappaB activation. Evaluation of PD components revealed that sodium lactate and glucose-degradation products impaired the acquisition of maturation parameters and NF-kappaB activation in a dose-dependent manner. Moreover, PD solutions impaired monocyte-MDDC differentiation, inhibiting the acquisition of DC markers such as CD1a and DC-specific intercellular adhesion molecule-3 grabbing nonintegrin (CD209). These findings have important implications for the initiation of immune responses under high lactate conditions, such as those occurring within tumor tissues or after macrophage activation.
67 citations
••
TL;DR: Las recomendaciones SER incluyen la osteoporosis secundaria a glucocorticoides, the osteopOrosis premenopausica y the del varon, y se emitieron siguiendo la metodologia de grupos nominales.
67 citations
••
TL;DR: El consenso GesEPOC-GEMA sobre ACO proporciona una vision unitaria del problema, con una propuesta conceptual sencilla y un algoritmo diagnostico pragmatico, aplicable en cualquier nivel sanitario de nuestro ambito.
Abstract: Resumen A instancias de la Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR), promotora de la Guia espanola de la EPOC (GesEPOC) y de la Guia Espanola para el Manejo del Asma (GEMA), autores de ambas guias han unificado criterios diagnosticos del solapamiento asma y EPOC (Asthma-COPD Overlap [ACO]). Este consenso define al ACO como la coexistencia en un mismo paciente de tres elementos: tabaquismo, limitacion cronica al flujo aereo y asma. La confirmacion diagnostica se establece cuando un paciente (≥ 35 anos) fumador o exfumador (≥ 10 paquetes-ano) presenta obstruccion o limitacion cronica al flujo aereo (FEV1/FVC post-broncodilatador Se solicito la opinion (mediante encuesta Delphi modificada) a otros 33 expertos que no habian participado en la elaboracion del consenso. Un 80% de estos lo valoro positivamente, incluso superior a otras propuestas recientes. El consenso GesEPOC-GEMA sobre ACO proporciona una vision unitaria del problema, con una propuesta conceptual sencilla y un algoritmo diagnostico pragmatico, aplicable en cualquier nivel sanitario de nuestro ambito.
67 citations
Authors
Showing all 9020 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jaakko Tuomilehto | 115 | 1285 | 210682 |
Vincent Soriano | 87 | 762 | 34084 |
Lina Badimon | 86 | 682 | 35774 |
Francisco J. Blanco | 84 | 789 | 33319 |
Michael A. Gatzoulis | 82 | 478 | 32562 |
Jose Lopez-Sendon | 81 | 460 | 41809 |
Victor Moreno | 80 | 635 | 31511 |
Joaquín Dopazo | 75 | 396 | 24790 |
Fernando Rodríguez-Artalejo | 74 | 512 | 23296 |
José R. Banegas | 74 | 421 | 28249 |
Michael Becker | 72 | 317 | 18189 |
Gianfranco Ferraccioli | 70 | 402 | 26515 |
Maria-Victoria Mateos | 66 | 480 | 24278 |
Manuel Romero-Gómez | 64 | 420 | 19006 |
Eulogio García | 63 | 270 | 15354 |